Bluebird Bio Inc (BLUE) 165.83 $BLUE bluebird b
Post# of 273327
Posted On: 08/01/2015 2:49:50 AM
Bluebird Bio Inc (BLUE) 165.83 $BLUE
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 6:27AM CDT
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy?
BLUE: 165.83 (+6.66)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMGN: 176.59 (+4.90), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19), CELG: 131.25 (-0.63)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), NBIX: 50.12 (+0.10), ISIS: 54.93 (+1.76), SRPT: 31.92 (+0.16), RCPT: 227.86 (+0.38)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 165.83 (+6.66)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 165.83 (+6.66), CELG: 131.25 (-0.63)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 165.83 (+6.66)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 165.83 (+6.66), DRNA: 12.22 (+0.20), ALNY: 127.43 (+1.97), TKMR: 10.83 (+0.58), JUNO: 48.92 (+1.15), CELG: 131.25 (-0.63)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 165.83 (+6.66), HZNP: 36.85 (+0.54), AAL: 40.10 (-0.17), SDRL: 8.91 (-0.43), HNT: 66.86 (+0.38)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 18.46 (+0.30), BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), AMGN: 176.59 (+4.90), JUNO: 48.92 (+1.15), SRNE: 20.78 (+0.39), XLRN: 28.64 (+0.54), CELG: 131.25 (-0.63)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 165.83 (+6.66), KITE: 72.77 (+1.47), ADMS: 24.76 (-0.17), ACHN: 8.52 (+0.13)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 165.83 (+6.66), GILD: 117.86 (-0.04), MNKD: 4.29 (-0.17), PBYI: 90.60 (+6.47), KERX: 7.98 (+0.23), CELG: 131.25 (-0.63)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 165.83 (+6.66), KITE: 72.77 (+1.47), CLLS: 35.74 (+1.27), JUNO: 48.92 (+1.15), CYAD: 55.33 (-0.29), CELG: 131.25 (-0.63)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 9.12 (+0.53), NFLX: 114.31 (+2.75), BLUE: 165.83 (+6.66), AMZN: 536.15 (-0.61), TSLA: 266.15 (-0.64), KITE: 72.77 (+1.47), LBIO: 8.56 (+0.40), JUNO: 48.92 (+1.15), EGRX: 96.62 (-0.16)
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 6:27AM CDT
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy?
BLUE: 165.83 (+6.66)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMGN: 176.59 (+4.90), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19), CELG: 131.25 (-0.63)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), NBIX: 50.12 (+0.10), ISIS: 54.93 (+1.76), SRPT: 31.92 (+0.16), RCPT: 227.86 (+0.38)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 165.83 (+6.66)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 9.12 (+0.53), BLUE: 165.83 (+6.66), AMBA: 115.87 (+0.07), NFLX: 114.31 (+2.75), EYES: 14.11 (-0.11), AMZN: 536.15 (-0.61), ZIOP: 13.36 (+0.46), LNKD: 203.26 (-23.89), FB: 94.01 (-1.20), RCPT: 227.86 (+0.38), LBIO: 8.56 (+0.40), INTC: 28.95 (+0.04), ONTY: 3.64 (+0.14), CELG: 131.25 (-0.63)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 165.83 (+6.66), NFLX: 114.31 (+2.75), AMZN: 536.15 (-0.61), TDOC: 31.57 (+0.66), GUID: 10.07 (+1.23), CBM: 49.25 (-0.68), FB: 94.01 (-1.20), LBIO: 8.56 (+0.40), GOOGL: 657.50 (-7.06), MBLY: 60.10 (+0.03), AAPL: 121.30 (-1.07)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 165.83 (+6.66), CELG: 131.25 (-0.63)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 165.83 (+6.66)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 165.83 (+6.66), DRNA: 12.22 (+0.20), ALNY: 127.43 (+1.97), TKMR: 10.83 (+0.58), JUNO: 48.92 (+1.15), CELG: 131.25 (-0.63)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 165.83 (+6.66), HZNP: 36.85 (+0.54), AAL: 40.10 (-0.17), SDRL: 8.91 (-0.43), HNT: 66.86 (+0.38)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 18.46 (+0.30), BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), AZN: 33.79 (+0.05), AMGN: 176.59 (+4.90), JUNO: 48.92 (+1.15), SRNE: 20.78 (+0.39), XLRN: 28.64 (+0.54), CELG: 131.25 (-0.63)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 165.83 (+6.66), KITE: 72.77 (+1.47), ADMS: 24.76 (-0.17), ACHN: 8.52 (+0.13)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 165.83 (+6.66), GILD: 117.86 (-0.04), MNKD: 4.29 (-0.17), PBYI: 90.60 (+6.47), KERX: 7.98 (+0.23), CELG: 131.25 (-0.63)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 165.83 (+6.66), KITE: 72.77 (+1.47), CLLS: 35.74 (+1.27), JUNO: 48.92 (+1.15), CYAD: 55.33 (-0.29), CELG: 131.25 (-0.63)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 9.12 (+0.53), NFLX: 114.31 (+2.75), BLUE: 165.83 (+6.66), AMZN: 536.15 (-0.61), TSLA: 266.15 (-0.64), KITE: 72.77 (+1.47), LBIO: 8.56 (+0.40), JUNO: 48.92 (+1.15), EGRX: 96.62 (-0.16)
(0)
(0)